The Role of Ischemia Modified Albumin As a Biomarker in Patients with Chronic Liver Disease

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2016 May 3

PMID 27134856

Citations 6

Authors

Prashanth Ashok Kumar

Kavitha Subramanian

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic Liver Disease (CLD) is characterised by gradual destruction of liver tissue over time. Ischemia Modified Albumin (IMA) is an upcoming biomarker shown to be elevated in conditions associated with ischemia and oxidative stress. Albumin levels are greatly reduced in patients with CLD and studying its alterations will provide essential information regarding the molecular changes occurring to it.

Aim: The study aims to estimate IMA and IMA/Albumin ratio in patients with CLD and to correlate it with parameters assessing liver function and the Model for End Stage Liver Disease (MELD) score.

Materials And Methods: The study consisted of 43 CLD patients as test subjects and 28 apparently healthy individuals as controls. Multiple parameters assessing liver function like albumin, bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), Gamma Glutamyl Transpeptidase (GGT), alkaline phosphatase (ALP), Prothrombin Time (PT) INR and creatinine were estimated and the MELD score calculated. Serum IMA expressed as Absorbance Units (ABSU) was estimated using the Albumin Cobalt Binding test (ABT). Student's t-test and correlation coefficient was used for statistical analysis.

Results: Serum IMA was significantly higher in CLD patients (0.5320 ± 0.1677) as compared to the control group (0.3203 ± 0.1257) with a p-value of <0.0001. The IMA/Albumin ratio was also significantly higher (0.2035 ± 0.0970) in patients with CLD compared to control group (0.0714 ± 0.0283) with a p-value of <0.0001. IMA has a negative correlation with albumin. The IMA/Albumin ratio shows positive correlation with MELD score, bilirubin and ALP. There was no correlation with ALT, AST, GGT and PT INR.

Conclusion: Decreased serum albumin correlates with increase in IMA in CLD could indicate a qualitative change and not merely a quantitative reduction of albumin. IMA can serve as a biomarker to assess the disease severity and prognosis of CLD patients.

Citing Articles

Introducing critical proteins related to liver ischemia/reperfusion injury.

Arjmand B, Khodadoost M, Jahani Sherafat S, Rezaei Tavirani M, Ahmadi N, Rezaei Tavirani S Gastroenterol Hepatol Bed Bench. 2024; 17(1):87-92.

PMID: 38737933 PMC: 11080694. DOI: 10.22037/ghfbb.v17i1.2555.

Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.

Gradel K J Clin Med. 2023; 12(19).

PMID: 37834777 PMC: 10573484. DOI: 10.3390/jcm12196132.

Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression.

Zeng Z, Liu H, Xu H, Lu H, Yu Y, Xu X BMC Med Genomics. 2021; 14(1):84.

PMID: 33736632 PMC: 7977299. DOI: 10.1186/s12920-021-00907-0.

Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury.

Xiao L, Zhang F, Zhao Y, Zhang L, Xie Z, Huang K Sci Rep. 2020; 10(1):18128.

PMID: 33093629 PMC: 7582878. DOI: 10.1038/s41598-020-75141-2.

Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.

Li H, Wu F, Duan M, Zhang G Medicine (Baltimore). 2019; 98(21):e15314.

PMID: 31124925 PMC: 6571239. DOI: 10.1097/MD.0000000000015314.

References

Fedeli U, Schievano E, Lisiero M, Avossa F, Mastrangelo G, Saugo M . Descriptive epidemiology of chronic liver disease in northeastern Italy: an analysis of multiple causes of death. Popul Health Metr. 2013; 11(1):20. PMC: 3852117. DOI: 10.1186/1478-7954-11-20. View

Turedi S, Gunduz A, Mentese A, Caner Karahan S, Yilmaz S, Eroglu O . Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med. 2007; 25(7):770-3. DOI: 10.1016/j.ajem.2006.12.013. View

Cichoz-Lach H, Michalak A . Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014; 20(25):8082-91. PMC: 4081679. DOI: 10.3748/wjg.v20.i25.8082. View

Arora V, Kulkarni R, Cherian S, Pillai R, Shivali M . Hyperbilirubinemia in normal healthy donors. Asian J Transfus Sci. 2010; 3(2):70-2. PMC: 2920475. DOI: 10.4103/0973-6247.53875. View

Cakir M, Caner Karahan S, Mentese A, Sag E, Cobanoglu U, Polat T . Ischemia-modified albumin levels in children with chronic liver disease. Gut Liver. 2012; 6(1):92-7. PMC: 3286745. DOI: 10.5009/gnl.2012.6.1.92. View

Refaai M, Wright R, Parvin C, Gronowski A, Scott M, Eby C . Ischemia-modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery. Clin Chim Acta. 2005; 366(1-2):264-8. DOI: 10.1016/j.cca.2005.10.020. View

Quinlan G, Martin G, Evans T . Albumin: biochemical properties and therapeutic potential. Hepatology. 2005; 41(6):1211-9. DOI: 10.1002/hep.20720. View

Ivanov A, Korolenko E, Korolik E, Firsov S, Zhbankov R, Marchewka M . Chronic liver and renal diseases differently affect structure of human serum albumin. Arch Biochem Biophys. 2002; 408(1):69-77. DOI: 10.1016/s0003-9861(02)00533-7. View

Gunduz A, Turedi S, Mentese A, Altunayoglu V, Turan I, Caner Karahan S . Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med. 2008; 26(8):874-8. DOI: 10.1016/j.ajem.2007.11.023. View

10.

Chen C, Tsai W, Lin P, Shiesh S . The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med. 2011; 49(11):1817-21. DOI: 10.1515/CCLM.2011.675. View

11.

Prashanth A, Anand U . Clinical significance of ischemia modified albumin in critically ill patients with sepsis. Indian J Clin Biochem. 2015; 30(2):194-7. PMC: 4393393. DOI: 10.1007/s12291-014-0434-4. View

12.

Christenson R, Duh S, Sanhai W, Wu A, Holtman V, Painter P . Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem. 2001; 47(3):464-70. View

13.

Ellidag H, Eren E, Yilmaz N, Cekin Y . Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure. Redox Rep. 2014; 19(3):118-23. PMC: 6837664. DOI: 10.1179/1351000213Y.0000000083. View

14.

Uhing M . The albumin controversy. Clin Perinatol. 2004; 31(3):475-88. DOI: 10.1016/j.clp.2004.03.018. View

15.

Gowda S, Desai P, Hull V, Math A, Vernekar S, Kulkarni S . A review on laboratory liver function tests. Pan Afr Med J. 2011; 3:17. PMC: 2984286. View

16.

Gines P, Arroyo V . Is there still a need for albumin infusions to treat patients with liver disease?. Gut. 2000; 46(5):588-90. PMC: 1727922. DOI: 10.1136/gut.46.5.588. View

17.

Nicholson J, Wolmarans M, Park G . The role of albumin in critical illness. Br J Anaesth. 2000; 85(4):599-610. DOI: 10.1093/bja/85.4.599. View

18.

Lau T, Ahmad J . Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2014; 5:1-10. PMC: 3953735. DOI: 10.2147/HMER.S9049. View

19.

Ahmad P, Islam B, Allarakha S, Rabbani G, Dixit K, Moinuddin . Preferential recognition of peroxynitrite-modified human serum albumin by circulating autoantibodies in cancer. Int J Biol Macromol. 2014; 72:875-82. DOI: 10.1016/j.ijbiomac.2014.10.001. View

20.

Poller L, Ibrahim S, Keown M, Pattison A, Jespersen J . The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. J Thromb Haemost. 2010; 9(1):140-8. DOI: 10.1111/j.1538-7836.2010.04109.x. View